Published in J Immunol Methods on July 01, 2001
Seroepidemiology of human polyomaviruses. PLoS Pathog (2009) 4.62
Association of Merkel cell polyomavirus-specific antibodies with Merkel cell carcinoma. J Natl Cancer Inst (2009) 2.22
Antibodies to merkel cell polyomavirus T antigen oncoproteins reflect tumor burden in merkel cell carcinoma patients. Cancer Res (2010) 2.14
A cornucopia of human polyomaviruses. Nat Rev Microbiol (2013) 2.08
A phase I trial of a human papillomavirus DNA vaccine for HPV16+ cervical intraepithelial neoplasia 2/3. Clin Cancer Res (2009) 1.79
Biomarkers of HPV in head and neck squamous cell carcinoma. Cancer Res (2012) 1.76
Measurement of biomarker proteins for point-of-care early detection and monitoring of cancer. Analyst (2010) 1.73
Systematic cloning of Treponema pallidum open reading frames for protein expression and antigen discovery. Genome Res (2003) 1.44
Seroprevalence of 34 human papillomavirus types in the German general population. PLoS Pathog (2008) 1.44
Seroprevalence of trichodysplasia spinulosa-associated polyomavirus. Emerg Infect Dis (2011) 1.25
Genus beta human papillomaviruses and incidence of basal cell and squamous cell carcinomas of skin: population based case-control study. BMJ (2010) 1.18
Genome scale identification of Treponema pallidum antigens. Infect Immun (2005) 1.14
Human papillomavirus type 16 L1 capsomeres induce L1-specific cytotoxic T lymphocytes and tumor regression in C57BL/6 mice. J Virol (2003) 1.12
Dendritic cell-based tumor vaccine for cervical cancer II: results of a clinical pilot study in 15 individual patients. J Cancer Res Clin Oncol (2003) 1.10
No role for human papillomavirus in esophageal squamous cell carcinoma in China. Int J Cancer (2010) 1.06
Different serologic behavior of MCPyV, TSPyV, HPyV6, HPyV7 and HPyV9 polyomaviruses found on the skin. PLoS One (2013) 1.05
Serum antibody response following genital {alpha}9 human papillomavirus infection in young men. J Infect Dis (2011) 1.05
Case-control study of cutaneous human papillomaviruses in squamous cell carcinoma of the skin. Cancer Epidemiol Biomarkers Prev (2012) 1.04
Serum antibody response to Human papillomavirus (HPV) infections detected by a novel ELISA technique based on denatured recombinant HPV16 L1, L2, E4, E6 and E7 proteins. Infect Agent Cancer (2006) 0.99
Cerebrospinal fluid JC virus antibody index for diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol (2014) 0.99
Presence of DNA of human papillomavirus 16 but no other types in tumor-free tonsillar tissue. J Clin Microbiol (2005) 0.97
Does pretreatment seropositivity to human papillomavirus have prognostic significance for head and neck cancers? Cancer Epidemiol Biomarkers Prev (2008) 0.96
Seroepidemiology of Human Polyomaviruses in a US Population. Am J Epidemiol (2015) 0.96
Cutaneous human papillomavirus infection, the EVER2 gene and incidence of squamous cell carcinoma: a case-control study. Int J Cancer (2008) 0.95
High-throughput pseudovirion-based neutralization assay for analysis of natural and vaccine-induced antibodies against human papillomaviruses. PLoS One (2013) 0.93
Development of a nucleocapsid-based human coronavirus immunoassay and estimates of individuals exposed to coronavirus in a U.S. metropolitan population. Clin Vaccine Immunol (2008) 0.92
A longitudinal study of human papillomavirus 16 L1, e6, and e7 seropositivity and oral human papillomavirus 16 infection. Sex Transm Dis (2015) 0.89
Cutaneous alpha, beta and gamma human papillomaviruses in relation to squamous cell carcinoma of the skin: a population-based study. Int J Cancer (2013) 0.89
Case-control study of cutaneous human papillomavirus infection in Basal cell carcinoma of the skin. J Invest Dermatol (2013) 0.87
Identification of B-cell epitopes on virus-like particles of cutaneous alpha-human papillomaviruses. J Virol (2009) 0.87
Detection of antibodies against epidermodysplasia verruciformis-associated canine papillomavirus 3 in sera of dogs from Europe and Africa by enzyme-linked immunosorbent assay. Clin Vaccine Immunol (2008) 0.87
Coronavirus immunoreactivity in individuals with a recent onset of psychotic symptoms. Schizophr Bull (2009) 0.86
Allergies and risk of head and neck cancer. Cancer Causes Control (2012) 0.85
Sunlight exposure and cutaneous human papillomavirus seroreactivity in basal cell and squamous cell carcinomas of the skin. J Infect Dis (2012) 0.84
Helicobacter pylori antibody patterns in Germany: a cross-sectional population study. Gut Pathog (2014) 0.83
Seroprevalence of Merkel cell polyomavirus in the general rural population of Anyang, China. PLoS One (2014) 0.81
Partially assembled K99 fimbriae are required for protection. Infect Immun (2005) 0.80
Prospective evaluation of 64 serum autoantibodies as biomarkers for early detection of colorectal cancer in a true screening setting. Oncotarget (2016) 0.80
Direct human papillomavirus E6 whole-cell enzyme-linked immunosorbent assay for objective measurement of E6 oncoproteins in cytology samples. Clin Vaccine Immunol (2012) 0.79
Re-detection vs. new acquisition of high-risk human papillomavirus in mid-adult women. Int J Cancer (2016) 0.78
A coding variant in TMC8 (EVER2) is associated with high risk HPV infection and head and neck cancer risk. PLoS One (2015) 0.78
Evidence of the causal role of human papillomavirus type 58 in an oropharyngeal carcinoma. Virol J (2013) 0.77
Prior human polyomavirus and papillomavirus infection and incident lung cancer: a nested case-control study. Cancer Causes Control (2015) 0.77
The seroprevalence of human papillomavirus by immune status and by ethnicity in London. Infect Agent Cancer (2009) 0.77
Skin and mucosal human papillomavirus seroprevalence in persons with Fanconi Anemia. Clin Vaccine Immunol (2015) 0.77
Variability in the distribution of genes encoding virulence factors and putative extracellular proteins of Streptococcus pyogenes in India, a region with high streptococcal disease burden, and implication for development of a regional multisubunit vaccine. Clin Vaccine Immunol (2012) 0.77
A high-performance thioredoxin-based scaffold for peptide immunogen construction: proof-of-concept testing with a human papillomavirus epitope. Sci Rep (2014) 0.76
HLA-C -35kb expression SNP is associated with differential control of β-HPV infection in squamous cell carcinoma cases and controls. PLoS One (2014) 0.75
Geno- and seroprevalence of Felis domesticus Papillomavirus type 2 (FdPV2) in dermatologically healthy cats. BMC Vet Res (2016) 0.75
Clinical and epidemiological correlates of antibody response to human papillomaviruses (HPVs) as measured by a novel ELISA based on denatured recombinant HPV16 late (L) and early (E) antigens. Infect Agent Cancer (2008) 0.75
Evaluation of the diagnostic value of 64 simultaneously measured autoantibodies for early detection of gastric cancer. Sci Rep (2016) 0.75
Serum Antibodies to HPV16 Early Proteins Warrant Investigation as Potential Biomarkers for Risk Stratification and Recurrence of HPV-Associated Oropharyngeal Cancer. Cancer Prev Res (Phila) (2015) 0.75
SUMOylation in Giardia lamblia: A Conserved Post-Translational Modification in One of the Earliest Divergent Eukaryotes. Biomolecules (2012) 0.75
Cutaneous Human Papillomavirus Infection and Development of Subsequent Squamous Cell Carcinoma of the Skin. J Skin Cancer (2016) 0.75
Seroprevalence of Cutaneous Human Papillomaviruses and the Risk of External Genital Lesions in Men: A Nested Case-Control Study. PLoS One (2016) 0.75
The sero-epidemiology of human papillomavirus among Caucasian transplant recipients in the UK. Infect Agent Cancer (2009) 0.75
Validation of Serological Antibody Profiles Against Human Papillomavirus Type 16 Antigens as Markers for Early Detection of Cervical Cancer. Medicine (Baltimore) (2016) 0.75
Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. EMBO J (1995) 7.60
Purification and molecular cloning of the APO-1 cell surface antigen, a member of the tumor necrosis factor/nerve growth factor receptor superfamily. Sequence identity with the Fas antigen. J Biol Chem (1992) 3.48
Complete DNA sequence of lymphotropic papovavirus: prototype of a new species of the polyomavirus genus. Virology (1985) 2.53
A viral enhancer element specifically active in human haematopoietic cells. Nature (1985) 1.95
Biochemical engineering of the N-acyl side chain of sialic acid: biological implications. Glycobiology (2001) 1.93
Phase II trial of imiquimod and HPV therapeutic vaccination in patients with vulval intraepithelial neoplasia. Br J Cancer (2010) 1.89
UDP-GlcNAc 2-epimerase: a regulator of cell surface sialylation. Science (1999) 1.88
Titration of AAV-2 particles via a novel capsid ELISA: packaging of genomes can limit production of recombinant AAV-2. Gene Ther (1999) 1.73
Somatic diversification of immunoglobulins. Proc Natl Acad Sci U S A (1984) 1.59
Mutational analysis of the human immunodeficiency virus type 1 env gene product proteolytic cleavage site. J Virol (1990) 1.52
Cervical intraepithelial neoplasia, cervical carcinoma, and risk for patients with HLA-DQB1*0602,*301,*0303 alleles. Lancet (1993) 1.48
Seropositivity for human papillomavirus and incidence of subsequent squamous cell and basal cell carcinomas of the skin in patients with a previous nonmelanoma skin cancer. Br J Dermatol (2011) 1.45
Biosynthetic modulation of sialic acid-dependent virus-receptor interactions of two primate polyoma viruses. J Biol Chem (1995) 1.40
Marked differences in Betapapillomavirus DNA and antibody prevalence between patients with psoriasis and those with atopic dermatitis. Br J Dermatol (2011) 1.39
Evidence for efficient uptake and incorporation of sialic acid by eukaryotic cells. Eur J Biochem (2001) 1.32
Galactan-binding antibodies. Diversity and structure of idiotypes. J Exp Med (1983) 1.30
Inhibition of human immunodeficiency virus type 1 replication in human T cells stably expressing antisense RNA. J Virol (1991) 1.29
Antibodies against early proteins of human papillomaviruses as diagnostic markers for invasive cervical cancer. J Clin Microbiol (1998) 1.28
Geographical dependence of sequence variation in the E7 gene of human papillomavirus type 16. J Gen Virol (1992) 1.25
The cell surface receptor is a major determinant restricting the host range of the B-lymphotropic papovavirus. J Virol (1993) 1.14
A case-control study of betapapillomavirus infection and cutaneous squamous cell carcinoma in organ transplant recipients. Am J Transplant (2011) 1.13
Antibodies against oncoproteins E6 and E7 of human papillomavirus types 16 and 18 in patients with head-and-neck squamous-cell carcinoma. Int J Cancer (2000) 1.12
Effect of TA-CIN (HPV 16 L2E6E7) booster immunisation in vulval intraepithelial neoplasia patients previously vaccinated with TA-HPV (vaccinia virus encoding HPV 16/18 E6E7). Vaccine (2004) 1.11
Specific inhibition of human immunodeficiency virus type 1 replication by RNA transcribed in sense and antisense orientation from the 5'-leader/gag region. Biochem Biophys Res Commun (1990) 1.11
Epstein-Barr virus nuclear antigen 2-estrogen receptor fusion proteins transactivate viral and cellular genes and interact with RBP-J kappa in a conditional fashion. Virology (1995) 1.09
Consequences of a subtle sialic acid modification on the murine polyomavirus receptor. J Virol (1997) 1.08
TP53, EGFR, and KRAS mutations in relation to VHL inactivation and lifestyle risk factors in renal-cell carcinoma from central and eastern Europe. Cancer Lett (2010) 1.05
Serological association of beta and gamma human papillomaviruses with squamous cell carcinoma of the skin. Br J Dermatol (2008) 1.04
Tat- and Rev-directed antisense RNA expression inhibits and abolishes replication of human immunodeficiency virus type 1: a temporal analysis. J Virol (1992) 1.02
Characterization of a new human papillomavirus (HPV 41) from disseminated warts and detection of its DNA in some skin carcinomas. Int J Cancer (1988) 1.02
Antibodies against oncoproteins E6 and E7 of human papillomavirus types 16 and 18 in cervical-carcinoma patients from Russia. Int J Cancer (2000) 1.02
Improving stable transfection efficiency: antioxidants dramatically improve the outgrowth of clones under dominant marker selection. Nucleic Acids Res (1998) 1.01
Electrotransfection of human lymphoid and myeloid cell lines. Nucleic Acids Res (1988) 1.01
Differential sialylation of cell surface glycoconjugates in a human B lymphoma cell line regulates susceptibility for CD95 (APO-1/Fas)-mediated apoptosis and for infection by a lymphotropic virus. Glycobiology (1999) 1.00
Biological evidence for a causal role of HPV16 in a small fraction of laryngeal squamous cell carcinoma. Br J Cancer (2013) 1.00
Biosynthesis of N-acetylneuraminic acid in cells lacking UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase. Biol Chem (2001) 1.00
Characterization of a novel Hodgkin cell line, HD-MyZ, with myelomonocytic features mimicking Hodgkin's disease in severe combined immunodeficient mice. J Exp Med (1993) 0.99
kappa-Chain restriction in anti-galactan antibodies. J Immunol (1982) 0.98
Lack of type-specific concordance between human papillomavirus (HPV) serology and HPV DNA detection in the uterine cervix and oral mucosa. J Gen Virol (2011) 0.97
Spontaneous regression of CIN and delayed-type hypersensitivity to HPV-16 oncoprotein E7. Lancet (2000) 0.97
Characteristic pattern of chromosomal gains and losses in primary large B-cell lymphomas of the gastrointestinal tract. Blood (1998) 0.96
Human papillomavirus type 16 E5 protein localizes to the Golgi apparatus but does not grossly affect cellular glycosylation. Arch Virol (2000) 0.95
Fast and high-affinity binding of B-lymphotropic papovavirus to human B-lymphoma cell lines. J Virol (1995) 0.94
Regulation of susceptibility and cell surface receptor for the B-lymphotropic papovavirus by N glycosylation. J Virol (1994) 0.94
Human papillomavirus type 18 E6 and E7 antibodies in human sera: increased anti-E7 prevalence in cervical cancer patients. J Clin Microbiol (1991) 0.93
A general purification protocol for E7 proteins from "high- and low-risk" human papillomavirus types expressed in the yeast Schizosaccharomyces pombe. Protein Expr Purif (1997) 0.92
T-cell receptor beta variable region diversity in melanoma metastases after interleukin 2-based immunotherapy. Clin Cancer Res (1996) 0.90
Expression of Epstein-Barr virus nuclear antigen-2 (EBNA2) induces CD21/CR2 on B and T cell lines and shedding of soluble CD21. Eur J Immunol (1995) 0.90
Genome structure and host range restriction of the lymphotropic papovavirus (LPV): identification of a viral lymphocyte specific enhancer element. Curr Top Microbiol Immunol (1984) 0.90
A monoclonal antibody that defines an idiotope with two subsites in galactan-binding myeloma proteins. J Exp Med (1981) 0.89
MedB-1, a human tumor cell line derived from a primary mediastinal large B-cell lymphoma. Int J Cancer (2001) 0.89
Suppression of Burkitt's lymphoma tumorigenicity in nude mice by co-inoculation of EBV-immortalized lymphoblastoid cells. Int J Cancer (1995) 0.89
Risk factors for HIV infection in gynaecological inpatients in Dar es Salaam, Tanzania, 1988-1990. East Afr Med J (1992) 0.88
E6/E7 expression of human papillomavirus types in cutaneous squamous cell dysplasia and carcinoma in immunosuppressed organ transplant recipients. Br J Dermatol (2006) 0.88
Suitability of Epstein-Barr virus-based episomal vectors for expression of cytokine genes in human lymphoma cells. Gene Ther (1997) 0.85
Local growth of a Burkitt's lymphoma versus disseminated invasive growth of the autologous EBV-immortalized lymphoblastoid cells and their somatic cell hybrids in SCID mice. Int J Cancer (1992) 0.85
Risk of seropositivity to multiple oncogenic human papillomavirus types among human immunodeficiency virus-positive and -negative Ugandan women. J Gen Virol (2011) 0.85
Efficient biochemical engineering of cellular sialic acids using an unphysiological sialic acid precursor in cells lacking UDP-N-acetylglucosamine 2-epimerase. FEBS Lett (2001) 0.85
Elongation of the N-acyl side chain of sialic acids in MDCK II cells inhibits influenza A virus infection. Biochem Biophys Res Commun (1998) 0.84
Detection of individual virus-infected cells by filter in situ hybridization. Mol Cell Probes (1988) 0.84
Host range restriction of the lymphotropic papova virus (LPV) in cells of human hematopoietic origin. Haematologica (1988) 0.84
Determination of the binding affinity of different human papillomavirus E7 proteins for the tumour suppressor pRb by a plate-binding assay. J Virol Methods (2001) 0.84
[Juvenile laryngeal papillomatosis--immunisation with the polyvalent vaccine gardasil]. Laryngorhinootologie (2008) 0.83
TP53 and EGFR mutations in combination with lifestyle risk factors in tumours of the upper aerodigestive tract from South America. Carcinogenesis (2009) 0.83
Suppression of the malignant phenotype in somatic cell hybrids between Burkitt's lymphoma cells and Epstein-Barr virus-immortalized lymphoblastoid cells despite deregulated c-myc expression. Cancer Res (1990) 0.83
Primary gastric apoptosis-rich T-cell lymphoma co-expressing CD4, CD8, and cytotoxic molecules. Virchows Arch (2000) 0.82
High sensitivity detection of JC-virus DNA in postmortem brain tissue by in situ PCR. J Neurovirol (2000) 0.81
Bead-based multiplex genotyping of 58 cutaneous human papillomavirus types. J Clin Microbiol (2011) 0.81
Reliability of PCR-based detection of occult tumour cells: lessons from real-time RT-PCR. Melanoma Res (2001) 0.81
Factors associated with the seroprevalence of 26 cutaneous and two genital human papillomavirus types in organ transplant patients. J Gen Virol (2011) 0.81
Integration of Epstein-Barr virus in Burkitt's lymphoma cells leads to a region of enhanced chromosome instability. Ann Oncol (1997) 0.81
Hodgkin's lymphoma-derived tissue serially transplanted into severe combined immunodeficient mice. Blood (1993) 0.80
Structure-function relationships of HIV-1 reverse transcriptase determined using monoclonal antibodies. J Biol Chem (1992) 0.80
Testing for electrotransfection parameters by use of the fluorescent dye lucifer yellow CH. Anal Biochem (1989) 0.80
Human Golgi beta-galactoside alpha-2,6-sialyltransferase generates a group of sialylated B lymphocyte differentiation antigens. Eur J Immunol (1992) 0.79
Essential role of c-myc in ara-C-induced differentiation of human erythroleukemia cells. Leukemia (1994) 0.79
Down-regulation of integrated Epstein-Barr virus nuclear antigen 1 and 2 genes in a Burkitt lymphoma cell line after somatic cell fusion with autologous EBV-immortalized lymphoblastoid cells. Int J Cancer (1993) 0.78
Integration of Epstein Barr virus near the breakpoint of a translocation 11;19 in a Burkitt's lymphoma cell line. Cancer Genet Cytogenet (1993) 0.78
RGD-mutants of B-lymphotropic polyomavirus capsids specifically bind to alpha(v)beta3 integrin. Arch Virol (2004) 0.78
Antisense RNA-mediated inhibition of the replication of the human immunodeficiency virus type 1. Discussion of critical parameters. Ann N Y Acad Sci (1992) 0.78
Sequence variation in the E7 gene of human papillomavirus type 18 in tumor and non-tumor patients and antibody response to a conserved seroreactive epitope. Int J Cancer (1993) 0.77
T cell activation of primed rabbit blood lymphocytes by antigen. Exp Cell Biol (1979) 0.77
Stable nontumorigenic phenotype of somatic cell hybrids between malignant Burkitt's lymphoma cells and autologous EBV-immortalized B cells despite induction of chromosomal breakage and loss. Cancer Res (1998) 0.77
A stable flank of unstable lymphotropic papovavirus integration sites is associated with a cellular S1 nuclease-sensitive sequence. Virology (1992) 0.77
Antibodies against human papillomavirus type 16 and 18 E6 and E7 proteins in cervicovaginal washings and serum of patients with cervical neoplasia. Viral Immunol (2001) 0.77
Restriction of T cell receptor V beta repertoire in melanoma metastasis responding to immunotherapy. Melanoma Res (1995) 0.76
Feasibility and acceptance of cervicovaginal self-sampling within the German National Cohort (Pretest 2). Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz (2014) 0.76
Oral human papillomavirus infection in men might contribute to HPV serology. Eur J Clin Microbiol Infect Dis (2014) 0.76
Development of a blocking enzyme-linked immunosorbent assay for the detection of avian polyomavirus-specific antibodies. J Virol Methods (2000) 0.76
An analysis of clustering of betapapillomavirus antibodies. J Gen Virol (2010) 0.75
Suppression of the tumorigenic growth of Burkitt's lymphoma cells in immunodeficient mice by cytokine gene transfer using EBV-derived episomal expression vectors. Int J Cancer (2000) 0.75
Establishment and characterization of a new Epstein-Barr virus transformed cell line from a human B cell lymphoma. Blut (1990) 0.75
Establishment of a hybrid cell system between malignant Burkitt's lymphoma cells and nonmalignant lymphoblastoid cells. Haematol Blood Transfus (1989) 0.75
Prevalence of transformation zone Chlamydia trachomatis DNA and serum antibodies in Tanzanian gynaecological in-patients. J Trop Med Hyg (1995) 0.75